Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu

Megan Lindsay Falsetta Wood, Ph.D.

Contact Information

Phone Numbers

Office: (585) 273-5462

Faculty Appointments

Biography

Research

The Falsetta lab is committed to translational women’s health research. Our goal is to identify previously unknown mechanisms of disease for disabling vulvar conditions, namely vulvodynia and lichens. By understanding the mechanisms of disease we can 1) identify new targets for therapy, 2) better adapt current modalities of treatment for rapid improvements in care, and 3) create new metrics to identify disease at an early stage and objectively track disease progression and response to treatment. Our research focuses on the basic science of disease, while directly interfacing with the clinical experts delivering care.

Localized provoked vulvodynia (LPV) is characterized by acute and lasting pain in response to light touch of the vulvar vestibule (area immediately surrounding the vaginal opening), which is associated with a reduction in quality of life. Although women afflicted with LPV experience profound pain that negatively impacts their sexual health, they show no overt signs of disease. The origins of vulvodynia are poorly understood, and no current therapy targets the root of the disease or is completely curative, perhaps save surgical removal of the affected tissue. The goal of our research is to identify less invasive, ideally topical, therapies. We have determined that a persistent low level of inflammation, generally undetectable clinically, is a key contributor to vulvodynia. Mostly recently, we have uncovered evidence pointing to a defect in the ability to resolve this inflammation, which may be the product of alterations in the presence or abundance of the molecules that help resolve inflammation named specialized pro-resolving mediators (SPMs) and the receptors that recognize these SPMs. Exogenous SPM treatment can overcome such defects, reducing inflammatory markers in both tissue culture and mouse models of disease, as well as measures of pain in mice, suggesting SPMs are excellent therapeutic candidates. SPMs are naturally produced by the body through metabolism of omega-3 and omega-6 fatty acids and are safe. Although our work in this area is ongoing, our findings suggest vulvodynia is the product of “two hits.” The first hit involves exaggerated inflammatory signaling, rendering the vestibule hypersensitive to inflammatory stimuli, such that a woman’s own natural flora may elicit a response. We are currently focusing on investigating the second hit, involving dysregulation of the resolution machinery.

Lichen planus (LP) and lichen sclerosus (LS) are common inflammatory dermatoses of the vulva characterized by intense pruritus (itching), burning, and changes in the architecture of the vulvar anatomy. Architectural changes can cause a loss of plasticity of the vagina, loss of mobility of the clitoral hood and/or fusion to the clitoral glans, and urinary symptoms (e.g. incontinence, dysuria). Additional manifestations include ulcers, erosions, and pre-cancerous or cancerous lesions. The standard of care for patients with LP and LS is topical application of ultrapotent steroids, more frequently to start and tapering off to weekly maintenance dosing, increasing frequency with flares or complications. Therefore, these are lifelong disorders, requiring long term treatment and regular follow up. Currently, there are no curative treatments available, and any architectural changes occurring prior to or during treatment are irreversible. The causes of lichen dermatoses are not well understood. Although these diseases are considered scarring dermatoses and the architectural changes are referred to as “scars,” limited and conflicting information about the role of scarring in is available. There is some evidence to implicate alterations in scarring/wound healing in lichenoid vulvar disease, and our research in this area aims to evaluate the role of scarring in lichenoid disease by identifying specific pathways and targets that may be aberrant.

Credentials

Education

2004
BA | Alfred University
Biology

2009
PhD | University of Iowa Roy J. and Lucille A. Carver College of Medicine
Microbiology

Post-doctoral Training & Residency

2013 - 2015
Environmental Medicine, University of Rochester, School of Medicine and Dentistry

2010 - 2013
Center for Oral Biology, University of Rochester, School of Medicine and Dentistry

Awards

2017
National Vulvodynia Association Research Fund Award

2015
International Society for the Study of Vulvovaginal Disease Best Candidate Abstract
Location: XXIII World Congress, New York University, New York, NY

Publications

Journal Articles

7/2/2018
Duffney PF, Falsetta ML, Rackow AR, Thatcher TH, Phipps RP, Sime PJ. "Key roles for lipid mediators in the adaptive immune response." The Journal of clinical investigation.. 2018 Jul 2; 128(7):2724-2731. Epub 2018 Jul 02.

1/2018
Falsetta ML, Foster DC, Woeller CF, Pollock SJ, Bonham AD, Piekna-Przybylska D, Maggirwar SB, Haidaris CG, Phipps RP. "Toll-Like Receptor Signaling Contributes to Proinflammatory Mediator Production in Localized Provoked Vulvodynia." Journal of lower genital tract disease.. 2018 Jan 0; 22(1):52-57.

1/2017
Falsetta ML, Foster DC, Bonham AD, Phipps RP. "A review of the available clinical therapies for vulvodynia management and new data implicating proinflammatory mediators in pain elicitation." BJOG : an international journal of obstetrics and gynaecology.. 2017 Jan 0; 124(2):210-218. Epub 2016 Jun 17.

VIEW ALL PUBLICATIONS